Xenon Pharmaceuticals (NASDAQ: XENE) — Perfil da empresa, notícias e dados financeiros
Xenon Pharmaceuticals develops therapeutics for neurological disorders, focusing on innovative treatments to improve patient outcomes.
Xenon Pharmaceuticals
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Their research and development efforts are primarily centered around leveraging proprietary technologies to create drugs that can address conditions such as epilepsy, Parkinson's disease, and other rare neurological diseases. Operating at the cutting edge of medical research, Xenon is dedicated to advancing a pipeline of neurology-focused treatments through clinical trials, with the ultimate objective of delivering new therapeutic options that can significantly improve patient outcomes. The company's commitment to science and medicine drives its pursuit of breakthroughs that can transform the treatment landscape for neurological conditions.
Resumo
Operações
Produtos e/ou serviços de Xenon Pharmaceuticals
- XEN1101, a novel Kv7 potassium channel opener designed for the treatment of epilepsy and potentially other neurological disorders.
- XEN496, a Kv7 potassium channel opener, specifically formulated for the treatment of KCNQ2 epileptic encephalopathy.
- XEN007 (active ingredient flunarizine), a calcium channel blocker being studied for the treatment of various neurological disorders, including hemiplegic migraine.
- Partnership with Neurocrine Biosciences to develop treatments for epilepsy, focusing on advancing novel Kv7 potassium channel modulators.
- Collaboration with Flexion Therapeutics to develop and commercialize treatments for osteoarthritis, leveraging Xenon's expertise in ion channel modulators.
- Research and development in the field of ion channel modulators, aimed at discovering innovative therapies for neurological conditions, emphasizing Xenon's commitment to addressing unmet medical needs.
equipe executiva do Xenon Pharmaceuticals
- Ian C. MortimerPresident, CEO & Director
- Thomas Patrick KellyChief Financial Officer
- Andrea DiFabioChief Legal Officer & Corporate Secretary
- Christopher John KenneyChief Medical Officer
- Darren S. ClineChief Commercial Officer
- Matthew D. RonsheimChief Operating Officer
- Shelley McCloskeyExecutive Vice President of Human Resources
- Robin P. SherringtonExecutive Vice President of Strategy & Innovation
- James R. EmpfieldExecutive Vice President of Drug Discovery
- Colleen AlabisoSenior Vice President of Corporate Affairs
Últimas notícias sobre a Xenon Pharmaceuticals
Principais indicadores financeiros
Resultados divulgados pela Xenon Pharmaceuticals, em USD.
- Cap. de mercado
- 3,5 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -4.7
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,5 mi | -373,1 mi | -345,9 mi | |
| 0 | -279,3 mi | -234,3 mi | |
| 0 | -214,1 mi | -182,4 mi | |
| 9,4 mi | -129,1 mi | -125,4 mi |